Organ preservation solutions are used to protect organs prior to transplantation because organs in the outer environment often collapse once removed from the human body. Organ conservation plans are implemented to save and maintain the value of organs for future applications such as transplantation and research. The development of organ preservation technologies is expected to be fueled by growing interest in organ transplantation procedures across the globe. Similarly, developing mechanically propelled techniques for saving organs support the market growth for organ preservation solutions.
Dr. Franz Koehler Chemie GmbH and Bridge to Life Ltd.- Notable Market Players in Organ Preservation Solution Market
The Organ Preservation Solution market majorly consists of the players such as Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, 21ST CENTURY MEDICINE, Shanghai Genext Pharmaceutical Technology, Bridge to Life Ltd., Perfusion Solutions, Inc., Lifeline Scientific, to Life Ltd. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the Organ Preservation Solution market:
|
Year |
News |
|
Aug-22 |
Paragonix Technologies, Inc. announced a significant milestone of preserving over 2,000 donor organs while also providing transplant hospitals with Advanced Organ Preservation (AOPT) technology and a statewide clinical support network. Each of these technologies employs first-of-their-kind preservation methods and has proven to improve conventional ice and cooler practices significantly. |
|
Jun-22 |
Paragonix Technologies, Inc. expanded the adoption of their LIVERguard Donor Liver Preservation System at the 2022 American Transplant Congress in Boston, Massachusetts. Since the commercial introduction of the LIVERguard system in January 2022, the advanced donor organ preservation system has been utilized at 8 U.S. transplant centers, including UF Health Shands, one of the largest liver transplant centers in the world. Paragonix has also been partnering with numerous Organ Procurement Organizations to provide more access to this unique hypothermic preservation technology. |
|
Apr-22 |
TransMedics Group, Inc. received premarket U.S. Food and Drug Administration (FDA) approval of its OCS Heart System for use with organs from donors after circulatory death (DCD). The OCS Heart System is now approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death (DCD) hearts. |
|
Dec-21 |
XVIVO Perfusion partnered with Contatti Medical to expand its business and gain access to a comprehensive network of transplantation centers in Brazil. |
|
Feb-21 |
Bridge to Life, Ltd., and Tevosol, Inc., announced their merger to develop and commercialize groundbreaking new products for the organ transplantation community. The arrangement includes Bridge to Life's significant financial commitment to manufacture, trial, and launch Tevosol's portable ex-vivo lung perfusion (EVLP) machine and normothermic organ preservation platform |
